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Abstract
Neuroinflammation is the local reaction of the brain to infection, trauma, toxic molecules or
protein aggregates. The brain resident macrophages, microglia, are able to trigger an
appropriate response involving secretion of cytokines and chemokines, resulting in the acti-
vation of astrocytes and recruitment of peripheral immune cells. IL-1β plays an important
role in this response; yet its production and mode of action in the brain are not fully under-
stood and its precise implication in neurodegenerative diseases needs further characteriza-
tion. Our results indicate that the capacity to form a functional NLRP3 inflammasome and
secretion of IL-1β is limited to the microglial compartment in the mouse brain. We were not
able to observe IL-1β secretion from astrocytes, nor do they express all NLRP3 inflamma-
some components. Microglia were able to produce IL-1β in response to different classical
inflammasome activators, such as ATP, Nigericin or Alum. Similarly, microglia secreted IL-
18 and IL-1α, two other inflammasome-linked pro-inflammatory factors. Cell stimulation with
α-synuclein, a neurodegenerative disease-related peptide, did not result in the release of
active IL-1β by microglia, despite a weak pro-inflammatory effect. Amyloid-β peptides were
able to activate the NLRP3 inflammasome in microglia and IL-1β secretion occurred in a
P2X7 receptor-independent manner. Thus microglia-dependent inflammasome activation
can play an important role in the brain and especially in neuroinflammatory conditions.
Introduction
Inflammatory processes have been implicated in both acute and chronic neurodegenerative
conditions. Pro-inflammatory cytokine production has been associated with neuroinflamma-
tion and different neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s
disease (PD) and Multiple Sclerosis (MS) [1–3]. Although inflammation may not typically rep-
resent an initiating factor in neurodegenerative diseases, there is emerging evidence in animal
models that sustained inflammatory responses involving microglia and astrocytes contribute to
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disease progression [4]. Among these responses, IL-1β secretion has been shown to have
important functions in diseases of the Central Nervous System (CNS), yet the precise mecha-
nism of action is not clear since both neurotoxic and regenerative roles have been described
[5–7].
The molecular steps leading to IL-1βmaturation take place in an intracellular complex
termed the inflammasome [8]. The inflammasome is a caspase-1 activating multiprotein plat-
form that results from oligomerization of inactive monomeric proteins from the nucleotide-
binding domain, leucine-rich repeat (NLR) protein family. Different complexes have been
described and are usually defined by the core NLR proteins that are implicated, such as
NLRP1, NLRP3, NLRC4 (also called IPAF) or the HIN200 family member AIM2. The most
intensively studied is the NLRP3 inflammasome which is formed when NLRP3 associates with
the adaptor protein ASC and procaspase-1 upon activation by different stimuli, such as patho-
gen associated molecular patterns (PAMPs) or endogenous danger signals [9, 10]. Inflamma-
some assembly results in the cleavage of caspase-1 from its proform to its enzymatically active
form. This active caspase-1 then processes the cleavage of several substrates, such as pro-IL-1β
and pro-IL-18 into the mature cytokines IL-1β and IL-18. IL-1α, another IL-1 family member,
and High-mobility group box 1 (HMGB1) do not require cleavage by caspase-1 but their
release in response to certain stimuli is dependent on the inflammasome [11, 12]. All these
cytokines are shown to be important actors in different neurodegenerative diseases [13, 14].
The precise mechanism of inflammasome activation is not fully understood. NLRP3 can sense
a variety of molecular structures and it is thought that inflammasome activation occurs proba-
bly not through direct ligand-receptor interaction but rather the sensing of cellular homeostasis
disruption [15, 16].
The role of the NLRP3 inflammasome in CNS diseases has recently started to be investi-
gated in more detail. Several studies suggest a general involvement of the NLRP3 inflamma-
some in MS, a demyelinating inflammatory disease of the CNS. In experimental autoimmune
encephalomyelitis (EAE), a mouse model of MS, inflammasome-deficient mice are protected
from disease progression (reviewed in [17]). In addition to MS, the implication of the NLRP3
inflammasome in Alzheimer's disease has been shown both in vitro by the ability of amyloid-
beta (Aβ) peptides to activate the inflammasome [18] and in vivo in an AD mouse model
where NLRP3 knock-out mice were protected from spatial memory impairment and showed
decreased Aβ plaque burden [19].
In many cases, neurodegenerative diseases are related to an accumulation of protein aggre-
gates such as Lewy bodies in PD, senile plaques in AD or PrPsc in prion related-disease. As
shown in a recent study, PrP fibrils are able to induce inflammasome-dependent IL-1β secre-
tion in microglia, suggesting a role for the NLRP3 inflammasome in prion diseases [20, 21].
Besides, the capacity of similar aggregates, such as islet amyloid polypeptide (IAPP) in type II
diabetes, to activate NLRP3 inflammasome via abnormal phagocytosis and lysosomal rupture
mechanism has also been shown [22].
In view to understand the role played by IL-1β in neurodegenerative diseases, it is important
to characterize in detail the inflammasome expression and activation in CNS inflammatory
cells. Microglia are the resident macrophages of the brain and as such are described to secrete
IL-1β. Astrocytes are the most abundant cell type in the brain where they maintain CNS
homeostasis and provide neuronal support in healthy conditions. In the injured brain they play
important roles during glial scar formation, a process referred to as reactive astrogliosis [23].
However it is not entirely clear if astrocytes are able to produce IL-1β. In addition there are
only few studies about the role astrocytes can play during neuroinflammation with regard to
inflammasome activation [24]. Therefore we aimed to investigate the relative contribution of
NLRP3 Inflammasome Function in Brain Glia
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microglia and astrocytes to inflammasome activation in the context of neurodegenerative dis-
ease-related peptide stimulation.
Materials and Methods
Mice
C57BL/6JOlaHsd mice were from Harlan. Nlrp3-/- mice were provided by University of Lau-
sanne [25]. Casp1-/-/Casp11-/- (sn#016621) (hereafter referred to as Casp1-/-) and P2rx7-/-
(sn#005576) mice were obtained from The Jackson Laboratory (Bar Harbor, USA). All mouse
strains were housed and bred at the animal-housing facility of the University of Luxembourg
approved by the National Veterinary Inspection. All animal procedures were conducted in
strict accordance with the FELASA Guide for the Care and Use of Laboratory Animals. The
protocol was approved by the animal ethics and experimentation committee (AEEC) of the
University of Luxembourg. All efforts were made to minimize suffering. Newborn mice were
decapitated.
Cell cultures
Mixed glial cell cultures were prepared as previously described [26]. Briefly, after carefully
removing meninges and large blood vessels, the brains from newborn mice were pooled and
then minced in cold phosphate-buffered saline (PBS) solution. After mechanical dissociation
cell suspensions were washed and plated in complete medium (Dulbecco’s Modified Eagle
Medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, Gibco),
100 U/ml penicillin and 100 U/ml streptomycin, both from Lonza) at 37°C in a humidified
atmosphere containing 5% CO2. The culture medium was changed after three days of culture.
After 15 days, mixed glial cultures had reached confluence. Glial cells were separated by mag-
netic-activated cell sorting (MACS), as previously described [26]. Microglia were positively
selected using an anti-CD11b antibody, following the manufacturer’s instructions (Miltenyi),
and plated in mixed glial culture conditioned medium to be treated twenty-four hours later.
Astrocytes were negatively sorted during this process. The obtained “astrocyte-enriched cul-
tures” were plated in 75 cm2 flasks for seven days allowing the cultures to reach confluence.
After one week, the MACS procedure was repeated in order to reduce microglial contamina-
tion of the astrocyte population.
Neurosphere-derived astrocytes were prepared as described in [27]. Briefly, neurospheres
derived from embryonic neural stem cells were cultured and were differentiated to astrocytes
by plating them on poly-L-ornithine coated flasks in complete DMEM.
Bone-marrow derived macrophages (BMDM) were generated as previously described [28].
Cortical neuron cultures were prepared from E15 mouse embryos as previously described
[29].
In vitro stimulation experiments
Cells were primed with ultrapure LPS (10 ng/ml), P3C (100 ng/ml) (both from Invivogen), IL-
1β(10 ng/ml), TNFα(10 ng/ml), IFNγ (20 ng/ml) or a Complete Cytokine Mix (CCM: 10 ng/
ml IL-1β, 10 ng/ml TNFα and 20 ng/ml IFNγ) (all from R&D). Stimulation with inflamma-
some activators (ATP, Nigericin (both from Sigma-Aldrich), MSU (Invivogen), Alum (Pierce),
poly(dA:dT) (Invivogen)) was performed as indicated in the figure legends. The amyloid beta
peptide 25–35 and the reverse form 35–25 (Sigma-Aldrich) were dissolved in PBS and ali-
quoted at −20°C. The amyloid beta peptide 1–42 (Bachem) was used under oligomeric and
fibrillar form. Fibrillar form was obtained by incubation at 37°C during 7 days in DMEM. WT
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and A53T mutant α-synuclein were purchased from rPeptide. Aliquots were resuspended in
H2O to obtain a 100 μM solution. The preparation was incubated for 4 days at 54°C with shak-
ing to obtain fibrillar α-synuclein or was used directly for oligomeric α-synuclein activation.
Where indicated in the legends, cells were treated with high KCl (Sigma-Aldrich) medium or
inhibitors (N-acetyl cystein (NAC) 5 mM (Sigma-Aldrich), (L- 3- trans- (Propylcarbamoyl)
oxirane- 2- Carbonyl)- L- Isoleucyl- L- Proline Methyl Ester (Ca-074Me) 10 μM (PeptaNova),
or cytochalasin D (cytoD) 2 μM (Sigma-Aldrich)) 30 min prior to addition of ATP or Alum.
Real-time PCR
Total RNA was isolated using the Invisorb Spin Cell RNAMini Kit (Invitek) according to the
manufacturer’s protocol. Complementary DNA (cDNA) was synthesized from RNA samples
using the ImProm-II Reverse Transcription System (Promega). Gene expression was analyzed
using Bio-Rad iCycler (iQ5 Real-Time PCR Detection System, Bio-Rad Laboratories) with
SYBR Green Supermix (Promega). Expression was normalized relative to the housekeeping
gene L27. Primer sequences were designed using the Beacon Designer Software (Bio-Rad)
(Table 1).
Immunoblot analysis
Cell extracts and precipitated supernatants were analyzed by immunoblot using goat anti-IL-
1β (R&D), mouse anti-NLRP3 (Cryo-2), rabbit anti-ASC (AL177), mouse anti-Caspase-1 (Cas-
per-1) (all three from Adipogen), and mouse anti-alpha-tubulin (Abcam).
Protein quantification assays
Cell culture supernatants were assayed, at the indicated times, for the presence of cytokines by
using mouse IL-1β, TNFα, CXCL10 DuoSet ELISA and IL-1α DuoSet ELISA (all R&D) or IL-
18 ELISA (MBL) according to the manufacturer’s instructions. ATP was quantified in cell
supernatants using ATP Determination Kit (Life technologies).
Immunocytochemistry
Cells were cultured on poly-L-lysine coated coverslips and fixed with paraformaldehyde (4% in
PBS) after stimulation. Cells were incubated overnight at 4°C with Cy3-labeled mouse anti-
GFAP (1:800, Sigma-Aldrich), rabbit anti-Iba1 (1:200, Biocare Medical), goat anti-IL-1β
(1:100, R&D), mouse anti-NLRP3 (1:100), rabbit anti-ASC (1:200), mouse anti-Caspase-1
(1:300, all three Adipogen) and rabbit anti-HMGB1 (1:400, Abcam). After washing with PBS,
cells were incubated with anti-rabbit, anti-goat or anti-mouse secondary antibodies coupled to
either Cy3 or AlexaFluor 488 (Invitrogen). Cells were then washed with PBS and mounted
with DAPI-Fluoromount G (SouthernBiotech, USA), and observed under a LSM 510 META
inverted confocal microscope (Carl Zeiss Micro Imaging, Göttingen, Germany).
Statistical analysis
The significance of multiple treatments was analyzed by a one way analysis of variance (anova)
followed by Tukey’s or Dunnett’s multiple comparisons tests. If multiple treatments were
tested on different genotypes, a two-way anova was performed. The homoscedasticity and nor-
mality assumptions were assessed respectively by the Bartlett and Shapiro-Wilk tests. The sta-
tistical analysis of gene expression was performed on the delta-Ct values (Ctgoi-Cthkg) and the
analysis of protein quantification (Elisa) was performed on log-transformed concentrations (if
present, zero values were removed by adding an offset to the dataset equal to half the smallest
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Table 1. Primer sequences list
Gene Accession number Primers sequence
Aif1 NM_019467 dir : TTCCCAAGACCCACCTAG
rev : TCCTCATACATCAGAATCATTC
Aim2 NM_001013779 dir : ATAGGAGGAACAACAACAT
rev : GCCATCTTCTGCTACATA
Asc NM_011977 dir : AGGAGTGGAGGGGAAAGC
rev : AGAAGACGCAGGAAGATGG
Casp1 NM_009807 dir : AGGAATTCTGGAGCTTCAATCAG
rev : TGGAAATGTGCCATCTTCTTT
Casp4 NM_007609 dir : GCTCTTACTTCATCACTA
rev : AATATCTCGTCAAGGTTG
Cxcl10 NM_021274 dir: TTCTGCCTCATCCTGCTG
rev: AGACATCTCTGCTCATCATTC
Gfap NM_010277 dir : GGTTGAATCGCTGGAGGAG
rev : CTGTGAGGTCTGGCTTGG
Hmgb1 NM_010439 dir : TGGCAAAGGCTGACAAGGCTC
rev : GGATGCTCGCCTTTGATTTTGG
Il18 NM_008360 dir : ACCAAGTTCTCTTCGTTGAC
rev : TCACAGCCAGTCCTCTTAC
IL1a NM_10554 dir : AAGACAAGCCTGTGTTGCTGAAGG
rev : TCCCAGAAGAAAATGAGGTCGGTC
IL1b NM_008361 dir : GCTTCAGGCAGGCAGTATC
rev : AGGATGGGCTCTTCTTCAAAG
Il33 NM_133775 dir : CAATGACCAATCTGTTAGT
rev : CATAGTAGCGTAGTAGCA
Il6 NM_031168 dir : ACCGCTATGAAGTTCCTCTC
rev : CTCTGTGAAGTCTCCTCTCC
Itgam NM_008401 dir : TGGACGCTGATGGCAATACC
rev: GGCAAGGGACACACTGACAC
Nlrc4 NM_001033367 dir : GTCAAGTGTTATCCAAGTTA
rev : CGCTAATATCATAGTCATCAA
Nlrp1 NM_001004142 dir : GGTGTGCTGGTTGGTCTGC
rev : GTGCTGTGGTGGTCTGTGAG
Nlrp12 NM_001033431 dir : AAGAGATGAGATGCTACCTTGAGAG
rev : ATGCCAACACTTCCTCCTTCAC
Nlrp2 NM_177690 dir : AAGCCTGTAGAGGTCTTACTG
rev : ACTGTGTCCGTGTGGTTAC
Nlrp3 NM_145827 dir : GCTCCAACCATTCTCTGACC
rev : AAGTAAGGCCGGAATTCACC
Nlrp6 NM_001081389 dir : GGACGAGAGGAAGGCAGAG
rev : GCACACGAAGGGCACAAAG
Nos2 NM_011198 dir : AGCCCTCACCTACTTCCTG
rev : CAATCTCTGCCTATCCGTCTC
P2x7r AJ_009823 dir : GGACCCACAGAGCAAAGGAATC
rev : TCAGTAGGACACCAGGCAGAG
Ptgs2 NM_010927 dir : GCCTGGTCTGATGATGTATGC
rev : GAGTATGAGTCTGCTGGTTTGG
(Continued)
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non-zero concentration). Non normal data was analyzed by a non-parametric analysis of vari-
ance (Kruskal–Wallis test) followed by pairwise comparisons with Mann–Whitney U-tests and
Holm’s correction.
All statistical analyses were performed using R (http://www.r-project.org/) and differences
with p-values less than 0.05 were considered significant. All experiments have been performed
at least three times.
Results
Brain microglia, but not astrocytes, express NLRP3 inflammasome
components and substrates
In order to better understand inflammasome function in the brain, especially in the glial com-
partment, we aimed to analyze NLRP3, ASC and caspase-1 expression in the different cell
types. Expression of inflammasome components was monitored at both the transcript and the
protein level (Fig 1A and 1B). Microglia express inflammasome components NLRP3, ASC
(Pycard) and caspase-1, similarly to bone marrow-derived macrophages that were used as con-
trol cells (Fig 1A and 1B). ASC and caspase-1 were constitutively present in microglia, whereas
NLRP3 expression could be upregulated after priming with LPS. In addition to priming with
LPS we used a complete cytokine mix (CCM: IL-1β, TNFα and IFNγ) that was also able to
induce NLRP3 expression in microglia and BMDMs (Fig 1A and 1B).
In astrocytes however, although caspase-1 was expressed at low levels, only very weak levels
of NLRP3 and ASC transcript and almost no NLRP3 and ASC protein could be detected, sug-
gesting that these cells probably lack a functional NLRP3 inflammasome (Fig 1A and 1B).
CCM was used in order to prime astrocytes as they do only weakly express TLR4 (Figure A in
S1 File) and do not strongly respond to LPS stimulation [30]. However, we were still unable to
robustly prime the inflammasome in astrocytes, as shown by the very moderate upregulation
of NLRP3. Also priming of astrocytes with several other agents (e.g. P3C, as shown below), as
well as combinations thereof (e.g. CCM and P3C, data not shown), did not result in significant
expression of NLRP3 and/or IL-1β.
We further investigated expression of other inflammasome related proteins and found that
both microglia and astrocytes expressed similar transcript levels of the intracellular sensors
Aim2 and Nlrp1, whereas Nlrc4 was mainly expressed in microglia (Fig 1C). Interestingly,
Casp4 (caspase-11) mRNA could be upregulated in microglia and astrocytes after priming (Fig
1C and Figure C in S1 File). In addition, classical inflammasome substrates, such as Il1b and
Il18, were strongly induced by LPS priming in microglia. Il1b transcript remained virtually
undetectable in astrocytes after CCM priming and Il18 basal expression levels remained
unchanged after priming (Fig 1D). Il1a expression was inducible by LPS treatment in microglia
and by CCM treatment in astrocytes.Hmgb1 was expressed by both microglia and astrocytes at
Table 1. (Continued)
Gene Accession number Primers sequence
Rpl27 NM_011289 dir : ACATTGACGATGGCACCTC
rev : GCTTGGCGATCTTCTTCTTG
Tlr4 NM_021297 dir : TTCACCTCTGCCTTCACTAC
rev : CACTACCACAATAACCTTCCG
Tnf NM_013693 dir : GGTTCTGTCCCTTTCACTCAC
rev : TGCCTCTTCTGCCAGTTCC
doi:10.1371/journal.pone.0130624.t001
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Fig 1. Inflammasome components NLRP3, ASC and caspase-1 are expressed in microglia, but not in astrocytes.mRNA and/or protein expression of
inflammasome components and substrates NLRP1, NLRP3, NLRC4, ASC (Pycard), Aim-2, Caspase-1, Caspase-4, IL-1α, IL-1β, IL-18 and HMGB1, were
studied in mouse microglia, astrocytes, or bone-marrow derived macrophages (BMDM) after 6 hours of stimulation with LPS or Complete Cytokine Mix. RNA
was extracted and analyzed for gene expression, relative to L27, by Real-Time PCR (A, C, D). Bar graphs shown represent the mean ± SD. (B) NLRP3, ASC
and Caspase-1 expression were analyzed byWestern Blot and α-Tubulin was used as loading control. (E) Microglia were analyzed by immunofluorescence
for the expression of Iba1, NLRP3, ASC, Caspase-1, HMGB1 and IL-1β, nuclei are stained by DAPI, scale bar: 50μm. Data shown are the mean ± SD of at
least three independent experiments. *p<0.05 compared to control (ctrl).
doi:10.1371/journal.pone.0130624.g001
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mRNA and protein level (Fig 1D and 1E). Protein localization was monitored by immunocyto-
chemistry in microglia, where LPS priming resulted in morphological changes monitoring cell
activation, shown by both cell surface marker Iba1 and IL-1β expression (Fig 1E). The inflam-
masome components NLRP3, ASC and caspase-1, as well as HMGB1, were stained in control
microglia and LPS-primed cells (Fig 1E).
In addition to the glial compartment, primary cortical neurons were analyzed by RT-PCR
for the presence of inflammasome components and we could detect expression of Nlrp1, Nlrp2,
Nlrp6 and Aim2, whereas classical NLRP3 inflammasome components were only weakly
expressed (Figure C in S1 File)
These results thus indicate that microglia are competent to form a functional NLRP3
inflammasome, whereas for astrocytes this type of inflammasome is probably not formed and
its activation seems compromised.
Microglia can secrete IL-1β and IL-18 in an NLRP3 inflammasome-
dependent manner
As microglia are the brain resident macrophages and seem to express the minimal require-
ments for inflammasome activation, we investigated their ability to secrete IL-1β, IL-18 and IL-
1α in response to classical inflammasome stimuli. When treated with widely used inflamma-
some activators, such as ATP and Nigericin, we observed robust IL-1β secretion and caspase-1
cleavage in LPS primed microglia (Fig 2A). In addition, particulate stimuli, such as monoso-
dium urate (MSU) crystals or Alum, were also able to induce IL-1β secretion, although at lower
levels (Fig 2A and 2B). Treatment with these different activators also resulted in IL-18 secretion
by microglia (Fig 2C). Production of both IL-1β and IL-18 occurred in a NLRP3 inflamma-
some-dependent manner, as shown by the use of NLRP3- and caspase-1-deficient microglia,
where the production of these cytokines was strongly reduced (Fig 2B and 2C). As both IL-1β
and IL-1α are able to trigger the IL-1 receptor and their relative contributions in vivo are not
well understood, we aimed to know if microglia could also produce IL-1α in response to
inflammasome activation. We observed NLRP3 inflammasome-dependent production of IL-
1α in response to ATP and Nigericin (Fig 2D and data not shown). In response to MSU and
Alum, IL-1α was produced in a NLRP3- and caspase-1-independent manner, as also reported
by others [31] (Fig 2D and data not shown). Production of all these cytokines required priming
of microglia by LPS (Figure A in S2 File). Microglia also produced TNFα in response to these
treatments, but this occurred in a NLRP3- and caspase-1-independent manner (Figure B in S2
File).
Inflammasome-dependent IL-1β production in microglia occurred through similar mecha-
nisms than described in BMDMs. As expected, the P2X7 receptor was only required in
response to stimulation with ATP, whereas Nigericin, MSU and Alum activated the inflamma-
some in a P2X7R-independent manner (Fig 2E). Potassium efflux was necessary for efficient
inflammasome activation in microglia, as blocking it by addition of KCl to the extracellular
medium strongly reduced IL-1β secretion (Fig 2F). This effect occurred in part at the priming
step since we also observed reduced levels of pro-IL-1β (data not shown). Reactive oxygen spe-
cies (ROS) were implicated in the microglial inflammasome activation process, since interfer-
ing with ROS production by N-acetyl cystein (NAC) impaired IL-1β secretion induced by ATP
and Alum (Fig 2G and 2H). Lysosomal damage was implicated in inflammasome activation by
Alum but not ATP, as shown by the use of the cathepsin B inhibitor Ca074-Me (Fig 2G and
2H). To determine if phagocytosis of Alum particles was required for inflammasome activa-
tion, we used the actin polymerization inhibitor cytochalasinD (cytoD). The presence of cytoD
selectively reduced IL-1β secretion in response to Alum (Fig 2H), but not ATP (Fig 2G).
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Fig 2. NLRP3 inflammasome activationmechanism in microglia. LPS primed microglia were stimulated
with ATP (1 mM, 30 min), Nigericin (Nig, 1.34 μM, 2 h), Monosodium urate (MSU, 100 μg/ml, 5 h) or
Aluminium hydroxide (Alum, 300 μg/ml, 5 h). IL-1β production and caspase-1 cleavage were assessed by
Western blot (A). Secretion of IL-1β (B), IL-18 (C) and IL-1α(D) in supernatants of wild-type (WT), Nlrp3-/- and
Casp1-/-microglia was assessed by ELISA. IL-1β secretion was assessed by ELISA in WT and P2rx7-/-
microglia (E) and after treatment with different inhibitors (F-H) (± KCl (25 mM), N-acetyl cystein (NAC, 5 mM),
Ca-074Me (10 μM) and cytochalasinD (cytoD, 2 μM)). Inhibitors were added for 30 min prior to inflammasome
activation. Data shown are the mean ± SD of at least three independent experiments. *p<0.05, ns = not
significant, compared to control (ctrl) (Fig 3B–3E) or compared to no treatment (Fig 3F–3H), #p<0.05, KO
compared to WT.
doi:10.1371/journal.pone.0130624.g002
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Amyloid-β induced microglial inflammasome activation is P2X7R-
independent
Inflammasome function has been linked to a number of diseases that are characterized by pep-
tide aggregates or particulate structures, such as gout or type 2 diabetes [32, 33]. Neurodegener-
ative conditions, such as Alzheimer’s or Parkinson’s disease, are known to involve plaques
formed by amyloid aggregates during the course of the disease [34]. In order to better under-
stand their potential role in the development of the disease and more specifically in microglial
activation, we treated cells with the amyloid-β fragment Aβ25–35. This Aβ peptide is unable to
prime microglia, as shown by the lack of upregulation of different genes, such as Nlrp3, Il1b or
Tnf upon treatment (Fig 3A). However, Aβ25–35 is able to induce caspase-1 cleavage and IL-1β
secretion in LPS primed microglia, whereas a control peptide (Aβ35–25) is not (Fig 3B and 3C).
IL-1β production is NLRP3- and caspase-1-dependent, as shown by the strong reduction of the
cytokine in inflammasome-deficient microglia (Fig 3D). However inflammasome activation by
Aβ is P2X7R-independent (Fig 3E); there is no requirement for this receptor either directly or
indirectly, as we could not detect ATP secretion in microglia treated with Aβ (Fig 3F). Opposed
to published results we were unable to detect significant IL-1β production by microglia treated
with the Aβ1–42 peptide whether we used oligomeric or fibrillar preparations of the peptide and
different time points (Fig 3G and 3H) [18, 35, 36].
α-synuclein can modestly prime microglia, but does not result in
significant IL-1β secretion
In addition to amyloid-β, we focused on the ability of α-synuclein (α-syn) to trigger inflamma-
some activation. α-syn is a component of Lewy bodies that are formed during Parkinson’s dis-
ease and we were interested in its pro-inflammatory capacities as an aggregated peptide.
Similarly to Aβ, α-syn can adopt different conformations such as oligomeric or fibrillar, and
different degrees of toxicity are associated with each form. We therefore tested both forms for
their ability to activate microglia. The oligomeric preparations showed slightly more transcrip-
tional activation than the fibrillar forms concerning certain genes, such as Tnf or Nlrp3 (Fig
4A). In addition to the native α-syn, we used a mutant peptide that occurs in familial forms of
PD, the A53T mutant, and observed that this form has more pro-inflammatory potential than
the WT form, but again only with the oligomeric conformation (Fig 4A). The same results
were observed for pro-IL-1β and NLRP3 at protein level, when both α-syn WT and A53T
forms (oligomeric and fibrillar) were used to treat microglia for longer time points (Fig 4B).
When using α-syn preparations for inflammasome activation, we did not observe significant
IL-1β secretion in LPS primed microglia in response to all tested preparations (Fig 4C).
Astrocytes do not secrete IL-1β or IL-18 in response to inflammasome
stimulation
As primary mixed glial cultures contain at least both glial cell types (astrocytes and microglia)
and as microglia are extremely reactive immune cells, it is important to deplete them as much
as possible from astrocyte cultures. Whereas microglia can be isolated to high purity by differ-
ent techniques, astrocyte cultures mostly remain “contaminated” by microglia [37]. In order to
analyze the purest possible astrocyte cultures in vitro, we performed double MACS isolation
where astrocytes were negatively selected during the sorting [26]. In this way we were able to
separate microglia and astrocytes efficiently starting from a mixed glial cell culture (MGC). We
analyzed expression of different cell type specific markers (Iba1 and CD11b for microglia and
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GFAP for astrocytes) in the microglia fraction and in the astrocyte enriched culture-double
MACS (AEC-M2), which were 98% and 99% pure respectively (Figures A and B in S1 File).
In order to prime astrocytes for inflammasome activation we tested different products, such
as LPS, P3C or different cytokines (IL-1β, TNFα and IFNγ) separately or in combination
(CCM), and we observed that CCM was the most efficient in this cell type (Fig 5A). CCM treat-
ment could induce transcriptional upregulation of Nlrp3, Casp-1, Il6, Nos2 and Cxcl10 (Fig 5A
and 5B), as well as the secretion of CXCL10 in the supernatant (Fig 5C). We were however
unable to detect substantial IL-1β or IL-18 secretion by CCM-primed astrocytes treated with
Fig 3. Amyloid-β25–35 activatesmicroglia to secrete IL-1β independently from P2X7 signaling. Untreated or LPS primed microglia were stimulated with
amyloid-β (Aβ)25–35 (20 or 50 μM) or Aβ35–25 (50 μM) for 5 h. (A) RNA was analyzed for expression of Nlrp3, Il1b and Tnf, relative to L27, by Real-Time PCR
(B) Cell free culture supernatants (SN) and cell lysates (XT) were analyzed byWestern Blot for expression of caspase-1 and IL-1β. α-Tubulin was used as
loading control. (C) IL-1β production in culture supernatants was assessed by ELISA. (D, E) IL-1β production in culture supernatants was assessed by ELISA
in wild type, Nlrp3-/- andCasp1-/- (D), or P2rx7-/- (E) microglia. (F) ATP release was quantified in cell supernatant upon treatment. (G) Untreated or LPS
primed microglia were stimulated with amyloid-β (Aβ) 1–42 (10μM) for 6h, 24h or 48h. IL-1β production in culture supernatants was assessed by ELISA. (H)
Cell free culture supernatants (SN) and cell lysates (XT) were analyzed byWestern Blot for expression IL-1β. α-Tubulin was used as loading control (I). Data
shown are mean ± SD of at least three independent experiments. *p<0.05 compared to control (ctrl), #p<0.05, KO compared to WT.
doi:10.1371/journal.pone.0130624.g003
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the NLRP3 inflammasome activators ATP, Nigericin, Aβ or the alternative activator α-synu-
clein (Fig 5D, 5E and 5G). In addition, treatment with the AIM2 inflammasome activator poly
(dA:dT) also failed to induce IL-1β or IL-18 secretion in astrocytes (Fig 5F and 5G). The sub-
stantial amounts of CXCL10 secreted by astrocytes in response to CCM indicate that these cells
can play important roles in the brain immune response, but are not able themselves to secrete
inflammasome-dependent cytokines, such as IL-1β or IL-18.
In order to differently address the question whether astrocytes are able to activate the classi-
cal NLRP3 inflammasome, we used neurosphere-derived astrocyte cultures [27]. When these
cells were treated with LPS or CCM, we observed very low or no expression of Asc and Il1b,
similarly to astrocyte-enriched cultures (Figure A in S2 File), suggesting again that astrocytes
do not express a functional NLRP3 inflammasome under these conditions.
Discussion
IL-1β production has been linked to neuroinflammatory conditions and neurodegenerative
diseases for a long time with both beneficial and detrimental effects described. However the
potential role of the NLRP3 inflammasome in the local production of IL-1β in the brain is not
very well understood. Recently several reports started to investigate inflammasome activation
in neuroinflammatory and neurodegenerative conditions, in spite of this fact a lot of basic
questions remain. We therefore aimed to characterize in more detail the in vitro capacities of
microglia and astrocytes separately to respond to inflammasome activation, since this issue has
not clearly been addressed. Especially concerning astrocytes, it is not clear if they are able to
express TLR4 and/or produce IL-1β as some conflicting reports exist [24, 38]. Analysis of this
phenomenon has often been complicated by the fact that, according to purification protocols
used, remaining microglia most probably "contaminate" astrocyte cultures. We observed that
Fig 4. α-synuclein is not an NLRP3 inflammasome activator.Microglia were stimulated with 5 μM α-synuclein (α-syn), either wild-type (α-syn WT) or
mutant (α-syn A53T) (oligomeric form: olig. or fibrillated form: fib.) for 6 h. (A) RNA was extracted and analyzed for expression of Nlrp3, Il1b and Tnf, relative
to L27, by Real-Time PCR. (B) After 6 h, 24 h or 48 h of stimulation with α-syn, or 6 h with LPS, cell lysates were analyzed byWestern Blot for expression of
pro-IL-1β and NLRP3. α-Tubulin was used as loading control. (C) LPS primed microglia were stimulated for 6 h with α-syn or for 30 min with ATP (1 mM) and
IL-1β production in culture supernatants was assessed by ELISA. Data shown are the mean ± SD of at least three independent experiments. *p<0.05
compared to control (ctrl).
doi:10.1371/journal.pone.0130624.g004
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less than 5% remaining microglia could result in detectable IL-1β production and therefore we
purified our astrocyte cultures by two successive MACS passages in order to carefully deplete
microglia. Recently, Facci and coworkers demonstrated that rat microglia-free astrocytes are
unable to secrete IL-1β, by depleting microglia with the lysosomotropic agent Leu-Leu-OMe, a
completely different approach than our MACS purification [39]. We were unable to observe
any substantial IL-1β and IL-18 secretion in astrocyte cultures in response to classical NLRP3
inflammasome stimuli. This could be due to the lack of ASC and weak NLRP3 expression in
these cells. In addition we could not induce pro-IL-1β expression in astrocytes, although we
tested several potential inducers, such as LPS, P3C or CCM, and longer time points. These
observations were confirmed in neurosphere-derived astrocyte cultures that are completely
devoid of microglia. It has also been shown that in human astrocytes IL-1βmRNA was not
translated to protein, probably by an active repression mechanism [40].
Concerning the role of other NLR proteins in the CNS, there is one report describing
NLRP2 inflammasome expression in human astrocytes [41]. We did however not detect
NLRP2 expression in our mouse astrocyte cultures, suggesting species-specific differences in
inflammasome components expression. Nlrp2 expression in the mouse seems to be restricted
Fig 5. Astrocytes are not able to secrete inflammasome substrates IL-1β and IL-18. Astrocytes were treated for 6h with LPS, P3C, IL-1β, TNFα, IFNγ or
CCM and RNA was extracted and analyzed for expression of Il6, Nos2, Cxcl10 (A), Il1b, Nlrp3 and IL18 (B) relative to L27, by Real-Time PCR. CXCL10
secretion was assessed after 6h or 24h of CCM treatment (C). Mouse astrocyte-enriched cultures (AEC-M2) and microglia were primed with Complete
Cytokine Mix for (24h) or LPS (6h), respectively, prior to stimulation with ATP (1 mM, 30 min), Nig (1,34 μM, 2h), Aβ25–35 (20 μM, 5h), WT and mutant α-
synuclein (5 μM, 5h) or poly(dA:dT) (1 or 2,5 μg/mL, 5h). Levels of IL-1β(D, E and F) and IL-18 (G) in culture supernatants were assessed by ELISA. Data
shown are the mean ± SD of at least three independent experiments *p<0.05 compared to control (ctrl).
doi:10.1371/journal.pone.0130624.g005
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to ovaries and plays a role in early embryonic development as a maternal effect gene [42]. We
were however able to detect NLRP1 expression in astrocytes, as also described before in several
reports that link NLRP1 inflammasome activation in astrocytes and neurons to in vivomodels
of spinal cord injury and thromboembolic stroke [43, 44]. In addition to classical inflamma-
some activators, such as ATP or Nigericin, we also tested AIM2 activation by the use of poly
(dA:dT) in astrocytes. In all cases, these potent microglial inflammasome activators did not
result in detectable IL-1β or IL-18 production in astrocytes. As both NLRP3 and AIM2 are
dependent on ASC in order to activate caspase-1, the lack of ASC in astrocytes could explain
this observation. ASC-independent inflammasomes, such as NLRP1 or NLRC4 inflamma-
somes that can directly engage caspase-1 could lead to induction of pyroptosis and/or cleavage
and secretion of IL-18. In addition the non-canonical inflammasome activation pathway could
be functional in astrocytes, as we could show that caspase-11 expression can be upregulated
upon priming.
A neuronal NLRP1 inflammasome has been described as a preassembled complex consist-
ing of NLRP1, caspase-1, ASC, caspase-11 and XIAP [44]. We could demonstrate expression of
ASC, caspase-1 and caspase-11 in cortical neurons, although they were weakly expressed. In
contrast, NLRP1, NLRP2 and Aim2 were relatively abundant in cortical neurons. Functional
analysis of these complexes has recently started and needs further characterization in order to
better understand the importance of inflammasomes in neurons and neuronal disorders [45].
Microglia share several features of peripheral macrophages when they are isolated in vitro.
They respond to classical NLRP3 inflammasome activation by secretion of IL-1β and other
cytokines, such as IL-18, IL-1α and TNFα. IL-1β and IL-18 production in response to particu-
late stimuli, such as MSU or Alum, is weaker than after activation with ATP or Nigericin. We
observed that microglial inflammasome activation occurs through similar mechanisms than in
BMDMs. We could show that potassium efflux, ROS production and cathepsin B function are
also required for efficient inflammasome activation in microglia.
A recent report showed that microglial IL-18 secretion in response to stimulation with S.
aureus is NLRP3- and ASC-independent [46]. In microglia, activation by S.aureus seems to
trigger additional pathways that can lead to mature IL-18, whereas in macrophages S.aureus
induced IL-18 production has been described to be NLRP3 inflammasome-dependent [47].
We show that IL-18 production in microglia in response to classical activators, such as ATP, is
NLRP3- and caspase-1-dependent as the corresponding knock-out microglia are no longer
able to secrete IL-18. As IL-18 is emerging as an important player in neuroinflammation, this
observation is clearly opening interesting questions concerning the differential production of
IL-18 in the brain [13].
We were interested in the potential implication of the NLRP3 inflammasome in neurode-
generative diseases and focused on in vitro activation of microglia and astrocytes by peptide
aggregates related to these conditions. Several reports already establish a link between amyloid-
β and inflammasome-dependent IL-1β secretion in macrophages and microglia [18, 35, 36].
Despite published reports we were unsuccessful in triggering inflammasome activation by the
full length peptide Aβ1–42. We tested fibrillar and oligomeric forms from different providers
and were unable to detect IL-1β production in primary microglia. However, when we tested
the peptide fragment Aβ25–35, we could observe inflammasome activation consistent with
another report [35], as monitored by IL-1β secretion in microglia, but in a P2X7R-independent
way (Fig 3E). The in vivo relevance of the NLRP3 inflammasome in Alzheimer's disease has
recently been demonstrated in the APP/PS1 mouse model where NLRP3-deficient mice show
less severe disease symptoms [19]. The conformation of Aβ peptides seems to be of great
importance for immune activation in vitro and may explain the different results obtained [48].
In addition, several reports describe the ability of Aβ to directly prime microglia, resulting in
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proIL-1β production. We could not observe this with the Aβ 25–35 peptide we used (Fig 3A);
the Aβ 1–42 may have more pro-inflammatory capacities. However, priming microglia or mac-
rophages with LPS before activating the inflammasome with Aβmay be required for a robust
activation and detection of IL-1β in vitro, as suggested by several published studies [18, 35, 36,
49, 50].
In correlation to Aβ, we tested the capacity of α-synuclein, a PD-related peptide aggregate,
to activate the inflammasome in microglia. α-syn treatment did not result in mature IL-1β
secretion in our hands, although we tested different kinetics and concentrations. Opposed to
this are recent reports describing substantial triggering of the inflammasome by aggregated α-
syn in human monocytes and THP1 cells [51, 52]. One explanation might be the different
aggregation forms used in our study, in addition inflammasome activation in mouse macro-
phages and in human monocytes occurs through different mechanisms [53]. Astrocytes treated
with Aβ25–35 or α-syn, did not secrete any IL-1β or IL-18 (Fig 5E) and only very modest levels
of CXCL10 (data not shown), indicating that astrocytes do not strongly react to these peptides,
at least in vitro. During the course of neurodegenerative diseases, it may be that microglial
inflammasomes are preferentially activated in response to neuronal death and associated ATP
release rather than by the presence of senile plaques and aggregated peptides. A recent study
also underlines the fact that adult microglia considerably differ from neonatal microglia in
their gene signature and this could also explain functional differences in inflammasome activa-
tion in the adult diseased brain [54].
It remains crucial to analyze microglia-astrocyte crosstalk in vivo to fully understand the
importance of NLRP3 inflammasome function in the brain and the potential therapeutic inter-
ests in neurodegenerative diseases, yet our results suggest that microglia are the main cell type
in the brain responsible for IL-1β and IL-18 secretion.
Supporting Information
S1 File. Characterization of cell expression markers and inflammasome components in pri-
mary microglia, astrocytes and neurosphere-derived astrocytes. (Figure A) mRNA expres-
sion of Aif1, Itgam, Tlr4 (microglia markers) and Gfap (astrocyte marker) has been analyzed in
mixed glial cultures (MGC P0), in astrocyte-enriched cultures (AEC) after one (AEC-M1) or
two MACS purifications (AEC-M2) and in microglial cultures, relative to L27, by Real-Time
PCR. (Figure B) MGC P0, microglia and AEC-M2 were analyzed by immunofluorescence for
the expression of Iba1 and GFAP, nuclei are stained with DAPI. Data shown are representative
of at least three independent experiments. (Figure C) mRNA expression of inflammasome
components, substrates or related genes has been analyzed in microglia, astrocytes (AEC-M2),
BMDM and cortical neurons, after 6 h of stimulation with LPS for microglia and BMDM,
Complete Cytokine Mix for astrocytes, or in unstimulated neurons. Data in the table are given
as means of Ct ± SD. Data shown are representative of at least three independent experiments.
(TIF)
S2 File. Priming is required for inflammasome activation in microglia (Figure A) IL-1β,
IL-18 and IL-1α production in culture supernatants was assessed by ELISA in microglia
after stimulation with ATP (1 mM), Nigericin (Nig, 1.34 μM), Monosodium Urate (MSU),
100 μg/ml) or Aluminium hydroxide (Alum, 300 μg/ml), in cells either primed with LPS or
not. Data are means ± SD values of triplicate wells. (Figure B) TNF-α production in culture
supernatants was assessed by ELISA in microglia of wild-type, Nlrp3-/- or Casp1-/- mice. Data
are means ± SD values of triplicate wells. Data shown are representative of at least three inde-
pendent experiments. (Figure C) mRNA expression of Nlrp3, Pycard, casp1, Il1b and Il18 has
been analyzed in neurosphere-derived astrocyte cultures stimulated for 6h with LPS or CCM,
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relative to L27, by Real-Time PCR. Data are means ± SD values of at least three independent
experiments.
(TIF)
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